Jpmorgan Chase & CO Provention Bio, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 18, 2023	BUY	$6.7 - $24.21 $323,770 - $1.17 Million	48,324 Added 18.82%	305,059 $7.35 Million
Q1 2023 May 11, 2023	BUY	$6.7 - $24.21 $1.46 Million - $5.26 Million	217,431 Added 553.2%	256,735 $6.19 Million
Q4 2022 Feb 13, 2023	BUY	$4.52 - $10.57 $8,497 - $19,871	1,880 Added 5.02%	39,304 $416,000
Q3 2022 Nov 14, 2022	BUY	$3.43 - $5.62 $15,688 - $25,705	4,574 Added 13.92%	37,424 $168,000
Q2 2022 Aug 11, 2022	SELL	$3.65 - $7.3 $7,332 - $14,665	-2,009 Reduced 5.76%	32,850 $132,000
Q1 2022 May 11, 2022	BUY	$3.4 - $7.88 $21,352 - $49,486	6,280 Added 21.97%	34,859 $255,000
Q4 2021 Feb 10, 2022	BUY	$5.59 - $7.39 $11,789 - $15,585	2,109 Added 7.97%	28,579 $160,000
Q3 2021 Nov 12, 2021	BUY	$5.66 - $8.33 $149,820 - $220,495	26,470 New	26,470 $169,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.